Obesity Medicine

Your daily dose of the clinical news you may have missed.

Michael Crotty, MD, provides practical guidance for on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan.

With the surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.

Obesity medicine specialist Michael Crotty, MD, discusses the benefits of GLP-1 receptor agonist use in weight management and its impact on obesity-related comorbidities.

Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.

At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.

Your daily dose of the clinical news you may have missed.

Teva announced approval of the generic formulation of Saxenda, which could help expand access to the extremely popular class of antiobesity medications.

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

In a trial of over 112 000 US adults, researchers found that 14% started a GLP-1 receptor agonist after bariatric surgery.